These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25609564)

  • 1. Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
    Morbelli S; Conzi R; Campus C; Cittadini G; Bossert I; Massollo M; Fornarini G; Calamia I; Marini C; Fiz F; Ghersi C; Derchi LE; Sambuceti G
    Cancer Imaging; 2014 Apr; 14(1):10. PubMed ID: 25609564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination.
    Rangaswamy B; Fardanesh MR; Genden EM; Park EE; Fatterpekar G; Patel Z; Kim J; Som PM; Kostakoglu L
    Laryngoscope; 2013 Nov; 123(11):2664-9. PubMed ID: 23553147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging.
    Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Klein M; Bares R; Claussen CD; Eschmann SM
    Br J Radiol; 2007 Jun; 80(954):437-45. PubMed ID: 17329683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
    Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
    Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.
    Chiaravalloti A; Danieli R; Caracciolo CR; Travascio L; Cantonetti M; Gallamini A; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
    Medicine (Baltimore); 2014 Aug; 93(8):e50. PubMed ID: 25121354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
    Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
    Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction.
    Müller J; Hüllner M; Strobel K; Huber GF; Burger IA; Haerle SK
    Laryngoscope; 2015 Aug; 125(8):1861-8. PubMed ID: 25892275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography.
    Goerres GW; Schuknecht B; Schmid DT; Stoeckli SJ; Hany TF
    Clin Imaging; 2008; 32(6):431-7. PubMed ID: 19006770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Morita S; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image-derived arterial input function in dynamic positron emission tomography-computed tomography: a method using both positron emission tomographic and computed tomographic images.
    Feng ST; Cui M; Gao J; Wu B; Sha W; Huang B
    J Comput Assist Tomogr; 2012; 36(6):762-7. PubMed ID: 23192217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.